EBV LMP2 131-139 Peptide (HLA-A*24:02) - PYLFWLAAI

The Epstein-Barr Virus (EBV) Latent membrane protein 2 (LMP2) Peptide is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Latent membrane protein 2 (LMP2) Peptide, H-PYLFWLAAI-OH (Uniprot: P13285 aa: 131-139) from JPT is produced under strict quality control and quality management.

EBV LMP2 131-139 Peptide (HLA-A*24:02) - PYLFWLAAI - Specifications

• Peptide sequence: H-PYLFWLAAI-OH
• Amount: 1 mg
• Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
• Delivery Format: Freeze-dried in plastic vial
• Application(s): T-cell immunity
• Condition(s)/Topic(s): Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Nasopharyngeal carcinoma, Infectious mononucleosis
• Standard Delivery Time: approx. 10 days

Visit our webpage for more information on Peptide Tools to Study EBV

Applications

• Antigen-specific CD8+ T-cell stimulation
• ELISPOT assays
• Intracellular cytokine staining (ICS)
• Cytotoxicity assays
• T-cell proliferation assays
• Immune monitoring in EBV-related research

Biological Function & Scientific Background

The EBV LMP2 131-139 epitope (PYLFWLAAI) represents a conserved antigenic region of the Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2), a viral protein expressed during latency and a key target of cellular immune responses. Presented by HLA-A*24:02 molecules, this epitope is recognized by cytotoxic CD8+ T lymphocytes, enabling precise analysis of antigen-specific T-cell responses.

Due to its defined immunogenicity, the LMP2 131-139 peptide is widely used to investigate T-cell activation, expansion, and effector function in viral immunology and oncology research. It plays an important role in studying immune surveillance mechanisms and supports the development of immunotherapeutic strategies targeting EBV-associated diseases, including malignancies and chronic infections.

Custom Peptide Services at JPT

In addition to catalog peptides such as the EBV LMP2 131-139 epitope (PYLFWLAAI), JPT offers comprehensive custom peptide synthesis services tailored to your research needs. Our expertise includes high-purity peptides, peptide pools, and modified sequences for immunological and therapeutic applications.

With advanced manufacturing capabilities and strict quality control, JPT supports a wide range of peptide-based research projects, including antigen discovery, T-cell assays, and vaccine development.

Scrambled PYLFWLAAI Peptide

For studies using the EBV LMP2 131-139 peptide (PYLFWLAAI), scrambled peptide controls can help distinguish specific CD8+ T-cell activation from non-specific background responses in assays such as ELISPOT, intracellular cytokine staining (ICS), and cytotoxicity assays.

JPT offers custom scrambled peptide design and synthesis services to support controlled and reproducible immunological experiments. Request for a quote here!